The matrix below pairs the five most common 2026 research objectives with the compound whose published Phase 2/3 data most directly answers it, anchored to SURMOUNT-1 (tirzepatide), STEP 1 (semaglutide), and Jastreboff et al
Reduced Abdominal Bruising Risk : If you experience bruising or sensitivity in the abdomen, the thigh can provide a good alternative to reduce the risk of these side effects
Plaintiffs argue that the manufacturers knew or should have known about these risks based on clinical data, adverse event reports, medical literature, and post-market safety information
Compounded medications are not reviewed or approved by the FDA as finished products
Ozempic (semaglutide) targets only the GLP1 receptor
Because different salt forms have different molecular weights